期刊
HEPATOBILIARY SURGERY AND NUTRITION
卷 10, 期 4, 页码 434-442出版社
AME PUBLISHING COMPANY
DOI: 10.21037/hbsn-21-188
关键词
Hepatocellular carcinoma (HCC); stereotactic therapy; PD-1; systemic therapy; conversion surgery
资金
- International Science and Technology Cooperation Projects [2016YFE0107100]
- CAMS Clinical and Translational Medicine Research Funds [2019XK320006]
- CAMS Innovation Fund for Medical Science (CIFMS) [2017-I2M-4-003, 2018-I2M-3-001]
- Beijing Natural Science Foundation [L172055, 7192158]
- Fundamental Research Funds for the Central Universities [3332018032]
- CSCO-Hengrui Cancer Research Fund [Y-HR2019-0239]
- National Tenthousand Talent Program
Combining tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies with local regional therapy has shown substantial clinical benefits in converting unresectable hepatocellular carcinoma patients with extrahepatic metastases to resectable. This study of HCC patients with oligometastatic disease utilizing this treatment strategy demonstrated promising outcomes, with a majority of patients surviving without recurrence and a subset achieving a pathological complete response after surgery. Adverse events were common but manageable, with fatigue, elevated aminotransferase levels, and hypertension being the most frequently reported.
Background: A combination of tyrosine kinase inhibitors (TKIs) and anti-PD-1 antibodies with local regional therapy has elicited yield substantial clinical benefits in patients who have hepatocellular carcinoma (HCC) with extrahepatic metastases. Using this treatment strategy to convert HCC patients with extrahepatic metastases from unresectable to resectable has not yet been reported. Methods: Consecutive hepatocellular carcinoma patients with extrahepatic metastases who received first-line therapy with a combination of TKIs and anti-PD-1 antibodies and at least one local regional therapy were analysed. Results: Nine patients with localized disease who received first-line systemic therapy were enrolled. At baseline, all of them had oligometastatic disease, namely, Barcelona Clinic Liver Cancer stage C (or Chinese Liver Cancer stage IIIB). The most common treatment administered was lenvatinib plus anti-PD-1 antibody and transarterial chemoembolization, and the median time span from systemic therapy to surgery was 3.2 (IQR, 2.8-6.2) months. Three patients achieved a pathological complete response. Six patients underwent laparoscopic surgery, and the other 3 patients underwent open surgery. After a median follow-up of 10.2 (IQR, 8.6-20.0) months, 7 patients survived without disease recurrence, and 2 experienced tumour recurrence. All patients had any-grade AEs, and 55.6% of the patients experienced grade 3 AEs. Fatigue was the most common AE, followed by elevated aminotransferase levels and hypertension. Conclusions: Stereotactic therapy is a feasible conversion therapy for HCC patients with extrahepatic metastases to become resectable. This is the first study to analyse therapeutic outcomes of patients receiving these therapies for HCC with extrahepatic metastases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据